Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...
Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...
Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.
Novo Nordisk has until 2023 before Victoza faces its first US biosimilars, by which time it hopes to have expanded the market for GLP-1s in established and emerging markets.
"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...
Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback